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Background. Ischemic mitral regurgitation is a condition characterized by mitral 
insufficiency secondary to an ischemic left ventricular.Primarily, the pathology is the result of 
perturbation of normal regional left ventricular geometry combined with adverse 
remodeling.We present a comprehensive review of contemporary surgical, medical, and 
percutaneous treatment options for ischemic mitral regurgitation, rigorously examined by 
current guidelines and literature. 
Methods. We conducted a literature search of the PubMed database, EMBASE and the 
Cochrane Library (through November 2018) for studies reporting perioperative or late 
mortality and echocardiographic outcomes following surgical and non-surgical intervention 
for ischemic mitral regurgitation. 
Results. Treatment of this condition is both challenging and often requires a multimodality 
approach.These patients usually have multiple comorbidities that may preclude surgery as a 
viable option.A multidisciplinary team discussion is crucial in optimizing outcomes.There are 
several options for treatment and management of ischemic mitral regurgitation with differing 
benefits and risks.Guideline-directed medical therapy for heart failure is the treatment choice 
for moderate and severe ischemic mitral regurgitation, with consideration of coronary 
revascularization, mitral valve surgery, and/or cardiac resynchronization therapy in 
appropriate candidates.The use of transcatheter mitral valve therapy is considered appropriate 
in high risk patients with severe ischemic mitral regurgitation, heart failure and reduced left 
ventricular ejection fraction especially in those with hemodynamic instability. 
Conclusions. The role of mitral valve surgery and transcatheter mit al valve therapy continues 
to evolve. 
Abstract word count: 223 
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Abbreviations: 
CABG= coronary artery bypass grafting  
IMR=ischemic mitral regurgitation  
LV=left ventricle 
LVEF=left ventricular ejection fraction 
MR=mitral regurgitation  
MV=mitral valve 
TEE=transoesophageal echocardiogram 















Optimal medical therapy has proven beneficial in patients with severe ischemic mitral 
regurgitation (IMR) presenting with heart failure and reduced left ventricular ejection fraction 
(LVEF).The mechanism of benefit appears to be by modulation of profibrotic changes of the 
tethered mitral valve, neurohormonal regulation andleft ventricular mass reduction1-
3.However, pharmacotherapy has limitations in IMR with reduced LVEF complicated by 
adverse reverse remodeling, especially in the presenc  of persistently reduced coronary 
perfusion4-6. 
The medical treatment options in IMR with reduced LVEF  include diuretics, beta-
blockade, and inhibition of the renin-angiotensin-aldosterone axis resulting in symptomatic 
improvement without the expectation of a substantial mortality benefit4,7-9.Surgical mitral 
valve (MV) replacement or repair combined with coronary artery bypass grafting (CABG) is 
considered the treatment of choice for low and intermediate-risk patients with severe IMR10-
12.Outcomes of surgical mitral valve repair plus CABG in patients with reduced LVEF and  
left ventricular (LV) remodeling are mixed and deserve careful evaluation13,14.In this high-risk 
cohort, determining the potential risk-benefit ratio for IMR therapy is difficult as the evidence 
is limited to registries and subgroup analyses of randomized clinical trials. An evolving 
catheter-based option for severe IMR with reduced LVEF is transcatheter mitral valve 
therapy15-18.The use of transcatheter mitral valve therapy is considered appropriate in high risk 
patients with severe IMR and reduced LVEF especially n patients with hemodynamic 
instability. It provides a less invasive approach which may be better tolerated in high-risk 
heart failure patients with IMR and LV dysfunction. Recently published clinical trial data 
have confirmed the benefit of transcatheter mitral valve therapy despite the discordance in the 
results of the two trials19,20.Enrolled patients primarily included those with severe secondary 
MR, reasonable life expectancy, and prohibitive surgical risk due to comorbidities. 
   
Material and Methods 
 Methodology of literature search and synthesis is enclosed in the Supplemental Material. 
                                                                                                                                                                                                     
Pathophysiology 
Ischemic mitral regurgitation is caused by the geomtric disturbance of valve and subvalvular 
apparatus of mitral valve. The imbalance between th tethering and closing forces is a 
consequence of adverse left ventricular remodeling after myocardial injury with enlargement 
of the left ventricle and mitral annulus, posterior and lateral displacement of the papillary 
muscles (PMs), leaflet tethering, and reduced closing forces.Leaflet coaptation is 
compromised resulting in varying degrees of mitral regurgitation21-(Figure 1; Panel I, 
II).These pathologic perturbations most commonly occur following ischemic events involving 
the left circumflex coronary artery, but may occur with lesions in the right coronary and left 
anterior descending coronary arteries depending on the coronary distribution to the 
posteromedial papillary muscle. MR resulting from such acute mitral valve distortion often 
resolves upon myocardial revascularization and resto ation of myocardial kinesis22,23.Despite 
revascularization, some myocardial segments may not rec ver sufficiently to reduce IMR 
which persists in with the onset of myocardial scarring.IMR, particularly in patients with 
reduced LVEF, commonly results in LV dilatation, a known independent risk factor for 
mortality12,22. 
Echocardiography-based studies have identified two types of restricted systolic leaflet motion 
according to the tethering shape: the asymmetrical pattern with predominant posterior 
tethering of both leaflets which is often observed with an inferior/posterior myocardial 
infarction, and the symmetrical pattern with predominant apical tethering most commonly 
seen with anterior myocardial infarctions22,24.Three tethering vectors (posterior, apical, and 
lateral) were observed in IMR and the displacement of one of the PMs exerts a traction and 
tethering effect on both MV leaflets.In the asymmetric type, the posterior leaflet is moved 
more posteriorly than apically due to its parallel position in respect to the posterior LV wall 
resulting in asymmetric tethering and an eccentric mitral regurgitant jet24-(Figure 1; Panel 
III).Conversely, in the symmetrical type there is a combination of apical and posterolateral 
vectorial tethering, with a more displaced coaptation point.The regurgitant jet is usually 
located centrally, and its direction reflects the equal involvement of the systolic motion in 
both leaflets24.(Figure 1; Panel IV) 
New experimental contributions are discussed in the supplemental material. 
 
Results 
Evaluation and Treatment 
International Guidelines 
The latest American College of Cardiology/American Heart association-(ACC/AH) and 
European Society of Cardiologists-(ESC) Guidelines-(2017) for the management of IMR 
support optimal medical therapy, surgical revascularization, and cardiac resynchronization as 
therapies that result in an improvement of MR severity.These therapeutic interventions 
improve regional wall motion, promote reverse LV remodeling and improve LV 
synchrony1,2.Figure 2-5 show the disease stages in patients with IMR and a proposed 
algorithm for management.  
Medical therapy of IMR with reduced LVEF   is discused in the supplemental material. 
Cardiac resynchronization 
Cardiac resynchronization Therapy-(CRT)  is a firmly established treatment choice  in 
selected patients with severe IMR and reduced LVEF who have LV dyssynchrony.The use of 
CRT is recommended by current guidelines and position papers of professional societies-
(Class I) in patients presenting in sinus rhythm with New York Heart Association-(NYHA) 
functional class II to IV symptoms on  guide direct medical therapy with LVEF ≤35%, left 
bundle branch block, and QRS duration ≥150ms. Moreover, clinical benefit after CRT 
implantation was noted in patients with sinus rhythm and non- left bundle branch block 
pattern with QRS duration ≥150ms, and in those with left bundle branch block and QRS 
duration 120 to 149 ms-(Class IIa recommendation)25. Randomized controlled trials have 
shown improvement in rehospitalization rates for heart failure and survival for CRT recipients 
(with and without defibrillator function)26,together with reduction in  LV end-diastolic and 
end-systolic dimensions and improved LVEF.Although most reports show reduced overall 
MR severity with restoration of synchronous ventricular contraction and LV remodeling, the 
effect of CRT implantation in secondary MR is inconsistent.One sham-controlled trial-
(MIRACLE/Multicenter InSync Randomized Clinical Evalu tion )27 included 450 patients in 
NYHA functional class III/IV and heart failure with LVEF ≤35% and QRS duration ≥130ms, 
reported a significant improvement in LV end-diastolic, LV end-systolic volumes and LVEF 
with preserved reduction in MR.Another study reported a significant reduction of secondary 
mitral regurgitation by restoring papillary muscle g ometry and altering the balance between 
the closing and tethering forces on the mitral valve28.The clinical benefit associated with the 
use of CRT was evident in no more than half of the patients, although this improvement 
identifies CRT recipients who have an improved prognosis29. Nonetheless, patients with 
severe IMR and heart failure with an EROA ≥0.20cm2 have a poor response to CRT alongside 
increased mortality and heart failure re-hospitalization rates. 
 
Surgery for ischemic secondary mitral regurgitation: when and how to treat? 
Combined revascularization and mitral surgery should be offered to patients with 
moderate-to-severe IMR with high-grade proximal coronary lesions.The indications for mitral 
valve surgery are limited due to the lack of a survival benefit.Therefore, surgical treatment for 
IMR is only recommended in patients who remain sympto atic despite optimal medical and 
device therapies1,2,13.The American Association of Thoracic Surgeon/ Society of Thoracic 
Surgeons-(AATS/STS)30 and ACC/AHA 2017  guidelines recommend that mitral valve 
surgery is reasonable for patients with chronic sever  ischemic MR-(stages C and D) 
undergoing CABG or aortic valve replacement-(Class IIa,LOE:C)1,10.The usefulness of 
surgical mitral repair is uncertain in patients with chronic moderate IMR-(stage-B) 
undergoing CABG-(Class IIb,LOE:B-R)1,11 
Mitral valve repair for IMR utilizing an undersized restrictive mitral annuloplasty ring, 
may be performed at the time of myocardial revascularization in patients with moderate IMR, 
although the overall benefit is certain 31-34.This is of particular concern for patients who are 
undergoing CABG with an LVEF≤ 30%35.Restrictive mitral annuloplasty is burdened by high 
rate of MR recurrence ranging from 30% to 40% at 6 to 12 months and about 60% at 5 
years10,12,22.Several causal factors of MR are identifiable on preo erative echocardiography: 
symmetric leaflet tethering,posterior leaflet tethering angle of >45°,tenting height >11 mm, 
presence of a basal aneurysm/dyskinesis,greater degree of LV dilation, and LV sphericity 
index22.MR recurrence  is  more frequent with use of partial annuloplasty bands or flexible 
complete rings36,37.High rates are also noted with complete rigid ring insertions10,12,38  
Observational, non-randomized, and single-center experiences are heterogenous in 
nature and contain many confounders that limit the quality of evidence.They lack robustness 
in study design, including non-rigorous definitions of the degree of MR especially in patients 
with moderate and severe degrees34,39,40.Michler et al published a randomized controlled trial 
(CTSN trial)11 of 301 patients with moderate ischemic MR undergoin  CABG, revealing a 
mortality rate of 10.0% in the group undergoing CABG plus mitral valve repair versus 10.6% 
after CABG alone at 2 year follow-up (HR in the combined-procedure group = 0.90; 95% CI: 
0.45 to 1.83; p=0.78).There was a higher rate of moderate or severe residual MR in the 
CABG-alone group (32.3% versus 11.2%;p<0.001), despit  imilar LV reverse 
remodeling.Although hospital readmission and serious adverse event rates were similar, 
neurological events and heart rhythm disorders were more frequent in patients undergoing 
CABG plus mitral valve repair suggesting that current vidence to support concomint mitral 
valve repair for moderate IMR at the time of CABG is weak11. 
Two other randomized controlled trials-(RCTs) are of particular interest: the 
Randomized Ischemic Mitral Evaluation-(RIME) trial31 and the POINT trial33.In these RCTs 
the authors demonstrated that the addition of restrictive mitral annuloplasty to CABG in 
patients with severe IMR resulted in improvements i LV reverse remodeling LVEF, New 
York Heart Association functional class-(NYHA), and MR grade, but not in survival.In the 
POINT trial 102 patients were randomly assigned to undergo CABG alone or CABG plus 
restrictive mitral annuloplasty.The CABG plus valve repair arm had significantly reduced LV 
end-systolic dimension-(LVESd).In the RIME trial, 73 patients were randomly assigned to 
undergo CABG alone or CABG plus valve repair.Their CABG plus restrictive mitral 
annuloplasty cohort demonstrated a 28% reduction in LV-end-systolic-volume index-
(LVESVI) compared to baseline. 
 The three randomized trials highlight that improvements in global and regional wall motion, 
as well as reverse LV remodeling after CABG with and without mitral valve repair, are 
indicative of viable myocardium.Penicka and colleagues noted that patients with moderate 
IMR who underwent CABG alone and experienced resolution of MR after surgery had more 
viable LV segments and less dyssynchrony at baseline41.Michler et al., similarly noticed that 
patients with resolution of IMR showed greater revese remodeling and better wall motion 
scores than those who did not regardless of the treatment group11.Given the importance of 
myocardial viability in ensuring good outcomes, theree RCTs deserve a more detailed 
analysis. 
Firstly, the number of patients enrolled in the studies differ widely, especially in the 
Cardiothoracic Surgical Trials Network-(CTSN) which enrolled three times the number of 
patients included in the other RCTs (CTSN =301, RIME =73 and POINT=102). Secondly, the 
clinical endpoints adjudicated in the studies were diff rent. CTSN utilized the Left 
Ventricular End Systolic Volume Index as the primary measure of outcome but POINT 
utilized the left ventricular end-systolic diameter-(LVESD), left ventricular end-diastolic 
diameter-(LVEDD), and left ventricular ejection fraction-(LVEF) as measures to elucidate 
reversal of LV remodelling.RIME’s primary endpoint was derived from cardiopulmonary 
exercise testing. POINT also assessed the tolerability to exercise in patients with residual MR 
of grade 2+ or less alongside variability of the MR grade during exercise and its effect on 
dyspnea and systolic pulmonary artery pressure whereas CTSN focused on echocardiographic 
measures using a wall motion score and using questionna res/patient reported outcomes to 
evaluate quality of life. Thirdly,different analytical statistical approaches were employed in 
the CTSN study, which included deceased patients as tre tment failures in the primary 
endpoint analysis, while the other studies utilised imple survival analyses. Fourthly, in the 
CTSN trial, recipients of surgical treatment had a significantly lower prevalence of prior 
myocardial infarction, potentially resulting in less LV scar tissue burden. Fifthly, and perhaps 
most importantly, patients in the CTSN trial had a baseline LV size that was less dilated and 
remodeled as compared with the POINT and RIME trials, respectively. 
All these variables favor CABG plus restrictive mitral annuloplasty, especially in the 
presence of extensive myocardial scar tissue-(figure-5). In fact, in these patients CABG alone 
would less likely result in an improvement in the LV wall motion and reverse remodeling, 
which favor a reduction in the burden of IMR42.As highlighted in the RIME trial, CABG plus 
papillary muscle approximation reduced the LV size by 28% from baseline, whereas in the 
CTSN trial CABG plus subvalvular repair was associated with only a 9% reduction.Patients 
in the CTSN trial had smaller ventricles at baseline a d, as the evidence suggests, more viable 
myocardium—precisely the clinical substrate that is likely to benefit most from CABG alone. 
Other factors such as the predicted probability of significant functional improvement should 
lead to the provision of a mitral valve reparative procedure.This category includes patients 
with documented scar tissue or basal aneurysm or dyskinesia in the inferoposterior lateral LV, 
large ventricles-(LVESVI>60 mL/m2 with left-ventricular-end-diastolic-diameter>50 mm), 
and poor coronary targets in the left circumflex and right coronary distributions,all of which 
reduce the likelihood that revascularization will provide significant enhancement of LV 
contractility and LV reverse remodeling12,22,42. 
In patients presenting with severe ischemic MR, mitral valve surgery (replacement or 
repair) combined with CABG is suitable-(figure-4,5). 2017 AHA/ACC Focused Update on 
VHD consider severe secondary MR an effective regurgitant orifice area-(EROA) > 0,4 cm2, 
a regurgitant volume-(Rvol) ≥ 60 ml and a regurgitant fraction-(RF) ≥ 50% while 2017 ESC 
Guidelines consider severe secondary MR an EROA ≥ 0,2 cm² or a Rvol ≥ 30 ml 
A CTSN randomized trial of surgical mitral valve repair versus surgical mitral valve 
replacement in 251 patients with severe IMR showed a mortality rate of 19.0% in the repair 
group and 23.2% in the replacement group-(p=0.39) at 2 years, with similar degrees of LV 
reverse remodelling10.The rate of recurrence of MR over 2 years was higher in the repair 
group (58.8% vs 3.8%,p<0.001), leading to a higher incidence of heart failure and repeat 
hospitalizations.Several valvular measures (e.g.,tenting area, anteroposterior annular diameter, 
coaptation length) and ventricular measures (e.g., LVESVI, LV-sphericity index, and 
interpapillary-muscle-distance) have been identified as possible predictors of recurrent mitral 
regurgitation in patients who undergo restrictive mitral annuloplasty alone using rings with a 
predefined geometry, which overcorrects for the increased tethering of the P2 and P3 
segments of the posterior mitral leaflet10,38,43.The high mortality rate at 2 years in both 
groups10 emphasizes the poor prognosis of IMR, which clearly differs from primary MR – the 
former being due to myocardial and coronary disease, nd latter a purely valvular condition. 
In patients with advanced NYHA class III-IV symptoms, isolated mitral surgery (replacement 
or repair) may be considered for patients who have persistent symptom despite optimal 
guideline-directed medical and cardiac resynchronization therapy in appropriate candidates-
(Class IIb;LOE-B)1,10.The experience of the surgeon, alongside consultation with the heart 
valve team, are critical in the  decision-making for surgical mitral valve repair versus surgical 
mitral valve replacement 10,12,22,36,39-42; however, it is reasonable to perform a chordal-spring 
MV replacement or MV repair in combination with a subvalvular procedure-(Class 
IIb;LOE:B-R)1,10,12,22,44,45-(figure-4,5). Surgical decision making for patients with IMR 
therefore could be enhanced by preoperative identification of those who would most likely 
have an improvement in regional wall motion and globa  LV function with combined 
CABG.Despite this, preoperative assessment of myocardial viability is often scarce in 
randomized controlled trials46.Viability assessment can predict the effectiveness of 
revascularization in specific patient populations, particularly within the present context37. 
The optimal valvular prosthesis for mitral valve replacement is unclear.Patients with 
IMR who undergo MV replacement with conventional stented prostheses may have worse 
hemodynamic performance and reduced functional capacity, when compared with patients 
who had a mechanical prosthesis implanted.However, th se data require prospective 
validation with long-term follow-up47.Prospective trials on subvalvular repair techniques are 
currently insufficient to derive definitive conclusions12,22,43.However, in patients with dilated 
ventricles (especially in those with scar tissue, dyskinesia, or a basal aneurysm) in whom 
surgical mitral valve repair is feasible, a subvalvular procedure such as papillary muscle 
approximation should be considered.Our previous analysis of patients who underwent CABG 
plus restrictive mitral annuloplasty with papillary muscle approximation identified 
echocardiographic preoperative symmetric tethering, the presence of a LV lateral wall 
dysfunction, persistent LV dyskinesis, and predominant apical tethering of both leaflets as 
independent predictors of recurrent mitral regurgitation48.Additionally, IMR recurrence after 
restrictive mitral annuloplasty with and without papillary muscle approximation is determined 
by persistent tethering of the posterior leaflet12,22,49-52.Aggressive annuloplasty ring under-
sizing causes a mismatch of the LV dimension and rig s ze increasing the risk recurrent 
IMR. Meticulous ring-sizing may prevent IMR recurrence after MV repair and correctly 
identify patients in whom combined restrictive mitral annuloplasty and sub-valvular 
intervention or chordal-sparing mitral valve replacement may be preferable.A recent post-hoc 
analysis by the CTSN authors noted that an LV end-systolic diameter/ring size ratio > 2 was 
associated with increased risk of persistent or recur nt IMR.Therefore, avoidance of smaller 
annuloplasty rings and incorporation of the LV size into surgical planning is prudent to 
improve repair durability and avoid iatrogenic mitral stenosis53.  
Our current decision algorithms for managing IMR focuses on 5 preoperative factors that 
help determine the surgical plan.In conjunction with echocardiography and cardiac 
catheterization, cardiac magnetic resonance imaging is useful for evaluating the following: 
1) severity of IMR  
2) severity of LV dysfunction  
3) severity of LV remodeling-(LVESVI)   
4) presence and extent of LV scar tissue  
5) Quality and distribution of the left circumflex and right coronary artery circulation 
(figure 4-5) 
Two extremes to the decision algorithms must be notd.Firstly, when medical treatment of 
IMR does not improve symptoms or quality of life, or progressive LV remodeling with 
increased LV dysfunction occurs, then heart transplantation or destination LV assist device 
therapy is a more effective treatment strategy as opposed to mitral valve 
surgery10,12,43.Secondly, in patients who have isolated inferobasal myocardial infarction and 
develop severe IMR due to posterior leaflet tethering despite normal LV size and function, the 
MR is the cause of heart failure and mitral valve surgery may be indicated for symptomatic 
relief10-12,38,42,43,54.The grey area consists of patients in between the described 
extremes.Particular attention is directed at patients with moderate-to-severe IMR with 
evolving symptomatology for which CABG is not indicated, representing a potential 
benchmark for transcatheter mitral valve therapy 19,20(figure-2,5). 
 
Non-surgical Intervention for secondary ischemic mitral regurgitation 
The aim of transcatheter mitral valve therapy is to develop a lower-risk procedure that 
effectively reduces the severity of MR and improve clinical outcomes.The increasing 
prevalence of MR in the elderly population with significant comorbidities has driven the 
attractiveness for transcatheter interventions.The transcatheter procedure is based on the 
surgical edge-to-edge mitral valve repair using a clip to approximate scallops of the anterior 
and posterior leaflets-(Figure-6). 
 
Results from TMVT-edge-to-edge repair from Randomized Controlled Trials 
To date, there are 3 RCTs comparing percutaneous TMV repair to optimal medical therapy or 
standard mitral valve surgery16,19,20-(Supplemental Table-1,2). COAPT-(Cardiovascular 
Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With 
Functional Mitral Regurgitation) and MITRA-FR-(Percutaneous Repair with the MitraClip 
Device for Severe Functional/Secondary Mitral Regurgitation) enrolled eligible patients with 
ischemic or non-ischemic cardiomyopathy who had a depressed LV ejection fraction, 
moderate-to-severe or severe secondary MR despite the administration of stable maximal 
doses of guideline-directed medical therapy and cariac resynchronization therapy.Baseline 
characteristics and results from these RCTs are reported in Supplemental table-1,2. 
The primary effectiveness endpoints of the COAPT study was all hospitalizations for heart 
failure within 24 months of follow-up, including recurrent events in patients with more than 
one event. In MITR-FR the primary effectiveness endpoints was composite of death from any 
cause or unplanned hospitalization for heart failure at 12 months after randomization. 
Baseline LV end-diastolic volume was higher in COAPT-(Mitraclip procedure versus medical 
therapy: 194.4±69.2 vs 191.0±72.9 ml) than the MITRA-FR study (136.2±37.4 vs.134.5±33.1 
ml).There was a marked difference in the rate of data available at 1 year of follow-up-
(COAPT > 94%; MITRA-FR < 55%)19,20. At 2-year follow-up in the COAPT study, Mitraclip 
procedure reduced the incidence of all-cause mortality by 38% ([HR] 0.62; 95% CI 0.46-0.92; 
p<0.001) and all-cause hospitalizations by 24% ([HR] 0.76; 95% CI 0.6-0.96;p=0.02), and 
was associated with significant LV reverse remodelling19 
The extraordinary results from COAPT were beyond the expectations of the authors 
themselves, because the rate of freedom from device-related complications with Mitraclip 
procedure exceeded their prespecified objective performance goal.Moreover, in the subgroup 
analysis, the benefits of transcatheter mitral valve therapy were consistent both in ischemic 
and non-ischemic cardiomyopathy, and in patients who ere considered high risk for surgery 
alongside low risk patients.This benefit was independent of the MR grade and LV volume and 
function at baseline19.Conversely, Obadia and colleagues reported that patients with severe 
secondary MR who received transcatheter mitral valve therapy in the MITRA-FR study did 
not experience a clinical benefit when compared with patients randomized to medical 
treatment alone.This result was consistent across all the subgroups tested.The missing data 
reported by Obadia et al., remains a cause for concern and results from the two trials should 
be interpreted within their respective contexts20.A complete description of the two trails is 
shown in supplemental table 2.  
The COAPT trial sheds light that an effective and sustainable percutaneous treatment can 
improve the prognosis and the risk of death of patients with secondary MR19.However, the 
main lesson of the Mitra-FR trial not all patients presenting with secondary MR will be 
improved by Mitraclip procedure20.The differences of these results can be explained by the 
different inclusion criteria of both studies that led to include two different populations of 
patients with secondary MR19,20. 
Patients included in the COAPT study19 presented with more severe MR-(EROA 0.41 cm2 vs. 
0.31 cm2 in the Mitra-FR study) and were treated more efficiently by transcatheter mitral 
valve therapy than in the Mitra-FR study (early recurrence of severe MR (grade 3/4): 5% vs. 
9%; one-year severe recurrence MR of severe MR (grade 3/4): 5% vs. 17%) 
respectively.Furthermore, in the COAPT trial, maximally optimized medical treatment was 
assessed before inclusion and randomization by a central adjudication committee including an 
heart failure specialist.The rigorous follow-up may have played a role in COAPT, an industry 
funded trial, accounting for its improved outcomes compared to the institutional RCT, 
MITRA-FR. 
The MITRA-FR study20 included some patients with less severe MR, more advanced LV 
disease with more dilated LVEDD-(135 mL/m2 vs 101 mL/m2) increased incidences of 
pulmonary hypertension.It is possible to surmise that ranscatheter mitral valve therapy was 
performed too late in the course of the heart failure disease in these patients.Finally, Grayburn 
et al55 recently reported that COAPT patients presented with a disproportionate number of 
secondary MR (severe MR and few dilated LV) while Mitra-FR patients presented with 
proportioned MR.In patients with disproportionate MR, the mitral disease is in the 
foreground, explaining that an effective and sustainable treatment may improve the 
prognosis.In patients with proportionate MR, the secondary MR is linked to the severity of 
LV disease and prognosis may not be linked to MR treatment55 
In the EVEREST-(Endovascular Edge-to-Edge Repair) II study16, transcatheter mitral valve 
therapy was compared to conventional mitral valve surgery although only 27% of patients 
have FMR.Results showed that the 5-year freedom frodeath, mitral valve surgery or 
reoperation, and moderate to severe MR was lower in the mitraclip group versus surgery 
group (44.2% vs. 64.3%; p=0.01).This was driven by lower rates of MV surgery or 
reoperation (95% vs. 72.1%; p=0.003) and moderate to s vere MR (98.2% vs. 87.7%;p=0.02), 
as opposed to survival (79.2% vs. 73.2%; p=0.36).Interestingly, a subgroup analysis showed 
the potential benefits of transcatheter mitral valve therapy having been derived in patients > 
70 years of age, with surgery performing better than percutaneous repair in younger patients 
(interaction p=0.005)16. 
Results from TMVT-edge-to-edge repair from observational and registry studies are reported 
in the supplemental material. 
 
Areas of Uncertainty and Future Direction 
Areas of uncertainty remain with regards to the optimal treatment in both populations with 
severe IMR because rigorous randomized trials of medical treatment versus surgery are 
lacking in patients not suitable for CABG with reduced LVEF and moderate-severe 
MR.Therefore, medical therapy, cardiac resynchronization therapy and revascularization 
when indicated, should be considered the preferred t eatment choice.  
Currently transcatheter mitral valve therapy of IMR is limited to edge-to-edge mitral valve 
repair, although new techniques could be extended to the annulus or chordae, either 
exclusively or in combination. 
Small studies using novel interventional therapies have demonstrated feasibility and 
efficiency in reducing MR and improving heart failure symptoms.The Carillion, Cardioband, 
and Mitralign devices were designed to reduce annular di atation, a frequent and important 
perpetuator of secondary MR-(Figure-3).Several transcatheter mitral valve replacement 
systems (Tendyne,CardiAQ-Edwards, Neovasc, Tiara, Intrepid, Caisson, High Life, MValve 
System, and NCSI NaviGate Mitral) are emerging as tr nscatheter valve replacement may 
offer more durability compared to transcatheter valve repair56 
 
Conclusion 
There are several options for treatment and management of IMR with differing 
prognostic benefits; however, patients who manifest IMR with heart failure and LV 
dysfunction have a worse prognosis.Guideline-directed medical therapy is the first treatment 
choice for moderate and severe secondary MR, with cardiac resynchronization therapy and 
coronary revascularization performed in appropriate c ndidates.The role of mechanical 
intervention, conventional surgery, or transcatheter mitral valve therapy are less clear and still 
evolving. Long-term follow-up of patients with secondary MR and ischemic cardiomyopathy 
receiving surgical or percutaneous intervention should be guided by consistent evaluations of 
valve durability, functional outcomes, and survival.Finally, better communication between 









Figure 1. Panel I: Carpentier type IIIb represents restricted leaflet motion in systole. Panel II 
Multi-modality echocardiographic imaging for IMR.TTE: para-sternal long axis view(A) and 
TEE-LVOT view(B) show eccentric jet of MR due to asymmetrical tethering. (C):3D TEE-« 
en face view from LA» showed marked indentations betwe n P2-P3 and P2-P1 (white arrow) 
due to LV remodeling (D):3D TEE-«en face view from LV» shows an apical and posterior 
secondary displacement of posterior papillary muscle (white arrow). (E-F): reconstruction and 
modelization of mitral valve shows the malcoaptation of mitral leaflets due to a tethering of 
the posterior valve. Panel III: Asymmetric pattern of mitral valve tethering on two- and three-
dimensional echocardiography in the inferior/posterior direction (yellow arrow) results in 
posteriorly-directed eccentric ischemic mitral regurgitation (IMR) (A-D). Panel IV: 
Symmetric pattern of mitral valve tethering on two- and three-dimensional echocardiography. 
Note central ischemic mitral regurgitant jet (Figures A-D).  
Figure 2. Overview of decision making for patients presenting with mitral regurgitation 
secondary to ischemic cardiomyopathy. Data were derived from Nappi F et al Ann Thorac 
Surg48 and Nappi F et al J Thorac Cardiovasc Surg22.  
Abbreviation. RHC = right heart catheterization; LVgram= left ventriculogram; 
MRI=cardiovascular magnetic resonance 
Figure 3. Decision-making of feasibility for high-risk patients suitable of percutaneous repair 
with transcatheter mitral valve therapy edge to edge. 
Figure 4. TTE evaluation for decision tree in assessing severity of chronic ischemic mitral 
regurgitation. 
Figure 5. Decisional algorithm for surgery of moderate to sever  IMR. 
Abbreviation. EROA=effective regurgitant orifice are ;RF=regurgitant fraction;RVol= 
regurgitant volume 
Figure 6. Percutaneous edge-to-edge mitral valve repair of a patient with IMR.3D-TEE (A) 
and 3D-TEE color (B) en-face view showing central secondary IMR.(C): 3D-TEE en-face 
view after a successful procedure with implantation of 2 central MitraClips.(D): TTE 3-
chamber view showing persistent good results at 1 year with residual mild MR and a gradient 
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